Equitable treatment for HIV/AIDS clinical trial participants: A focus group study of patients, clinician researchers, and administrators in western Kenya

D. N. Shaffer, V. N. Yebei, J. B. Ballidawa, John Sidle, J. Y. Greene, E. M. Meslin, S. J N Kimaiyo, W. M. Tierney

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or "what is fair" for study participants in an HIV/AIDS clinical drug trial. Design: Qualitative study with focus groups. Setting: Teaching and referral hospital and rural health centre in western Kenya. Participants: Potential HIV/AIDS clinical trial participants, clinician researchers, and administrators. Results: Eighty nine individuals participated in a total of 11 focus groups over a four month period. The desire for continued drug therapy, most often life long, following an HIV/AIDS clinical trial was the most common priority expressed in all focus groups. Patients with and without HIV/AIDS also thought subsidisation of drug therapies and education were critical forms of compensation for clinical trial participation. Financial incentives were considered important primarily for purchasing drug therapy as well as obtaining food. Patients noted a concern for the potential mismanagement of any money offered. Clinician researchers and administrators felt strongly that researchers have a moral obligation to participants following a trial to provide continued drug therapy, adverse event monitoring, and primary care. Finally, clinician researchers and administrators stressed the need for thorough informed consent to avoid coercion of study participants. Conclusions: Kenyan patients, clinician researchers, and administrators believe that it would be unfair to stop antiretroviral therapy following an HIV/AIDS clinical trial and that researchers have a long term obligation to participants.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalJournal of Medical Ethics
Volume32
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Kenya
study group
Focus Groups
Administrative Personnel
Acquired Immunodeficiency Syndrome
AIDS
Research Personnel
Clinical Trials
HIV
drug
Drug Therapy
obligation
Therapeutics
Moral Obligations
Rural Health Services
Coercion
Anti-HIV Agents
Group
AIDS/HIV
Administrators

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)

Cite this

Equitable treatment for HIV/AIDS clinical trial participants : A focus group study of patients, clinician researchers, and administrators in western Kenya. / Shaffer, D. N.; Yebei, V. N.; Ballidawa, J. B.; Sidle, John; Greene, J. Y.; Meslin, E. M.; Kimaiyo, S. J N; Tierney, W. M.

In: Journal of Medical Ethics, Vol. 32, No. 1, 01.2006, p. 55-60.

Research output: Contribution to journalArticle

Shaffer, D. N. ; Yebei, V. N. ; Ballidawa, J. B. ; Sidle, John ; Greene, J. Y. ; Meslin, E. M. ; Kimaiyo, S. J N ; Tierney, W. M. / Equitable treatment for HIV/AIDS clinical trial participants : A focus group study of patients, clinician researchers, and administrators in western Kenya. In: Journal of Medical Ethics. 2006 ; Vol. 32, No. 1. pp. 55-60.
@article{7b674e128d954baaac478d60037fe011,
title = "Equitable treatment for HIV/AIDS clinical trial participants: A focus group study of patients, clinician researchers, and administrators in western Kenya",
abstract = "Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or {"}what is fair{"} for study participants in an HIV/AIDS clinical drug trial. Design: Qualitative study with focus groups. Setting: Teaching and referral hospital and rural health centre in western Kenya. Participants: Potential HIV/AIDS clinical trial participants, clinician researchers, and administrators. Results: Eighty nine individuals participated in a total of 11 focus groups over a four month period. The desire for continued drug therapy, most often life long, following an HIV/AIDS clinical trial was the most common priority expressed in all focus groups. Patients with and without HIV/AIDS also thought subsidisation of drug therapies and education were critical forms of compensation for clinical trial participation. Financial incentives were considered important primarily for purchasing drug therapy as well as obtaining food. Patients noted a concern for the potential mismanagement of any money offered. Clinician researchers and administrators felt strongly that researchers have a moral obligation to participants following a trial to provide continued drug therapy, adverse event monitoring, and primary care. Finally, clinician researchers and administrators stressed the need for thorough informed consent to avoid coercion of study participants. Conclusions: Kenyan patients, clinician researchers, and administrators believe that it would be unfair to stop antiretroviral therapy following an HIV/AIDS clinical trial and that researchers have a long term obligation to participants.",
author = "Shaffer, {D. N.} and Yebei, {V. N.} and Ballidawa, {J. B.} and John Sidle and Greene, {J. Y.} and Meslin, {E. M.} and Kimaiyo, {S. J N} and Tierney, {W. M.}",
year = "2006",
month = "1",
doi = "10.1136/jme.2004.011106",
language = "English",
volume = "32",
pages = "55--60",
journal = "Journal of Medical Ethics",
issn = "0306-6800",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Equitable treatment for HIV/AIDS clinical trial participants

T2 - A focus group study of patients, clinician researchers, and administrators in western Kenya

AU - Shaffer, D. N.

AU - Yebei, V. N.

AU - Ballidawa, J. B.

AU - Sidle, John

AU - Greene, J. Y.

AU - Meslin, E. M.

AU - Kimaiyo, S. J N

AU - Tierney, W. M.

PY - 2006/1

Y1 - 2006/1

N2 - Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or "what is fair" for study participants in an HIV/AIDS clinical drug trial. Design: Qualitative study with focus groups. Setting: Teaching and referral hospital and rural health centre in western Kenya. Participants: Potential HIV/AIDS clinical trial participants, clinician researchers, and administrators. Results: Eighty nine individuals participated in a total of 11 focus groups over a four month period. The desire for continued drug therapy, most often life long, following an HIV/AIDS clinical trial was the most common priority expressed in all focus groups. Patients with and without HIV/AIDS also thought subsidisation of drug therapies and education were critical forms of compensation for clinical trial participation. Financial incentives were considered important primarily for purchasing drug therapy as well as obtaining food. Patients noted a concern for the potential mismanagement of any money offered. Clinician researchers and administrators felt strongly that researchers have a moral obligation to participants following a trial to provide continued drug therapy, adverse event monitoring, and primary care. Finally, clinician researchers and administrators stressed the need for thorough informed consent to avoid coercion of study participants. Conclusions: Kenyan patients, clinician researchers, and administrators believe that it would be unfair to stop antiretroviral therapy following an HIV/AIDS clinical trial and that researchers have a long term obligation to participants.

AB - Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or "what is fair" for study participants in an HIV/AIDS clinical drug trial. Design: Qualitative study with focus groups. Setting: Teaching and referral hospital and rural health centre in western Kenya. Participants: Potential HIV/AIDS clinical trial participants, clinician researchers, and administrators. Results: Eighty nine individuals participated in a total of 11 focus groups over a four month period. The desire for continued drug therapy, most often life long, following an HIV/AIDS clinical trial was the most common priority expressed in all focus groups. Patients with and without HIV/AIDS also thought subsidisation of drug therapies and education were critical forms of compensation for clinical trial participation. Financial incentives were considered important primarily for purchasing drug therapy as well as obtaining food. Patients noted a concern for the potential mismanagement of any money offered. Clinician researchers and administrators felt strongly that researchers have a moral obligation to participants following a trial to provide continued drug therapy, adverse event monitoring, and primary care. Finally, clinician researchers and administrators stressed the need for thorough informed consent to avoid coercion of study participants. Conclusions: Kenyan patients, clinician researchers, and administrators believe that it would be unfair to stop antiretroviral therapy following an HIV/AIDS clinical trial and that researchers have a long term obligation to participants.

UR - http://www.scopus.com/inward/record.url?scp=30644459710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644459710&partnerID=8YFLogxK

U2 - 10.1136/jme.2004.011106

DO - 10.1136/jme.2004.011106

M3 - Article

C2 - 16373525

AN - SCOPUS:30644459710

VL - 32

SP - 55

EP - 60

JO - Journal of Medical Ethics

JF - Journal of Medical Ethics

SN - 0306-6800

IS - 1

ER -